TY  - JOUR
AU  - Li, Hanluo
AU  - Masieri, Federica Francesca
AU  - Schneider, Marie
AU  - Bartella, Alexander
AU  - Gaus, Sebastian
AU  - Hahnel, Sebastian
AU  - Zimmerer, Rüdiger
AU  - Sack, Ulrich
AU  - Maksimović-Ivanić, Danijela
AU  - Mijatović, Sanja
AU  - Simon, Jan-Christoph
AU  - Lethaus, Bernd
AU  - Savković, Vuk
PY  - 2021
UR  - internal-pdf://Li et al. - 2021 - The Middle Part of the Plucked Hair Follicle Outer Root Sheath Is Identified as an Area Rich in Lineage-Specific Stem.pdf
UR  - https://www.mdpi.com/2218-273X/11/2/154
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/4149
AB  - Hair follicle outer root sheath (ORS) is a putative source of stem cells with therapeutic capacity. ORS contains several multipotent stem cell populations, primarily in the distal compartment of the bulge region. However, the bulge is routinely obtained using invasive isolation methods, which require human scalp tissue ex vivo. Non-invasive sampling has been standardized by means of the plucking procedure, enabling to reproducibly obtain the mid-ORS part. The mid-ORS shows potential for giving rise to multiple stem cell populations in vitro. To demonstrate the phenotypic features of distal, middle, and proximal ORS parts, gene and protein expression profiles were studied in physically separated portions. The mid-part of the ORS showed a comparable or higher NGFR, nestin/NES, CD34, CD73, CD44, CD133, CK5, PAX3, MITF, and PMEL expression on both protein and gene levels, when compared to the distal ORS part. Distinct subpopulations of cells exhibiting small and round morphology were characterized with flow cytometry as simultaneously expressing CD73/CD271, CD49f/CD105, nestin, and not CK10. Potentially, these distinct subpopulations can give rise to cultured neuroectodermal and mesenchymal stem cell populations in vitro. In conclusion, the mid part of the ORS holds the potential for yielding multiple stem cells, in particular mesenchymal stem cells.
PB  - MDPI AG
T2  - Biomolecules
T1  - The Middle Part of the Plucked Hair Follicle Outer Root Sheath Is Identified as an Area Rich in Lineage-Specific Stem Cell Markers
IS  - 2
VL  - 11
DO  - 10.3390/biom11020154
SP  - 154
ER  - 

@article{
author = "Li, Hanluo and Masieri, Federica Francesca and Schneider, Marie and Bartella, Alexander and Gaus, Sebastian and Hahnel, Sebastian and Zimmerer, Rüdiger and Sack, Ulrich and Maksimović-Ivanić, Danijela and Mijatović, Sanja and Simon, Jan-Christoph and Lethaus, Bernd and Savković, Vuk",
year = "2021",
abstract = "Hair follicle outer root sheath (ORS) is a putative source of stem cells with therapeutic capacity. ORS contains several multipotent stem cell populations, primarily in the distal compartment of the bulge region. However, the bulge is routinely obtained using invasive isolation methods, which require human scalp tissue ex vivo. Non-invasive sampling has been standardized by means of the plucking procedure, enabling to reproducibly obtain the mid-ORS part. The mid-ORS shows potential for giving rise to multiple stem cell populations in vitro. To demonstrate the phenotypic features of distal, middle, and proximal ORS parts, gene and protein expression profiles were studied in physically separated portions. The mid-part of the ORS showed a comparable or higher NGFR, nestin/NES, CD34, CD73, CD44, CD133, CK5, PAX3, MITF, and PMEL expression on both protein and gene levels, when compared to the distal ORS part. Distinct subpopulations of cells exhibiting small and round morphology were characterized with flow cytometry as simultaneously expressing CD73/CD271, CD49f/CD105, nestin, and not CK10. Potentially, these distinct subpopulations can give rise to cultured neuroectodermal and mesenchymal stem cell populations in vitro. In conclusion, the mid part of the ORS holds the potential for yielding multiple stem cells, in particular mesenchymal stem cells.",
publisher = "MDPI AG",
journal = "Biomolecules",
title = "The Middle Part of the Plucked Hair Follicle Outer Root Sheath Is Identified as an Area Rich in Lineage-Specific Stem Cell Markers",
number = "2",
volume = "11",
doi = "10.3390/biom11020154",
pages = "154"
}

Li, H., Masieri, F. F., Schneider, M., Bartella, A., Gaus, S., Hahnel, S., Zimmerer, R., Sack, U., Maksimović-Ivanić, D., Mijatović, S., Simon, J., Lethaus, B.,& Savković, V.. (2021). The Middle Part of the Plucked Hair Follicle Outer Root Sheath Is Identified as an Area Rich in Lineage-Specific Stem Cell Markers. in Biomolecules
MDPI AG., 11(2), 154.
https://doi.org/10.3390/biom11020154

Li H, Masieri FF, Schneider M, Bartella A, Gaus S, Hahnel S, Zimmerer R, Sack U, Maksimović-Ivanić D, Mijatović S, Simon J, Lethaus B, Savković V. The Middle Part of the Plucked Hair Follicle Outer Root Sheath Is Identified as an Area Rich in Lineage-Specific Stem Cell Markers. in Biomolecules. 2021;11(2):154.
doi:10.3390/biom11020154 .

Li, Hanluo, Masieri, Federica Francesca, Schneider, Marie, Bartella, Alexander, Gaus, Sebastian, Hahnel, Sebastian, Zimmerer, Rüdiger, Sack, Ulrich, Maksimović-Ivanić, Danijela, Mijatović, Sanja, Simon, Jan-Christoph, Lethaus, Bernd, Savković, Vuk, "The Middle Part of the Plucked Hair Follicle Outer Root Sheath Is Identified as an Area Rich in Lineage-Specific Stem Cell Markers" in Biomolecules, 11, no. 2 (2021):154,
https://doi.org/10.3390/biom11020154 . .

TY  - JOUR
AU  - Dinić, Jelena
AU  - Efferth, Thomas
AU  - García-Sosa, Alfonso T.
AU  - Grahovac, Jelena
AU  - Padrón, José M.
AU  - Pajeva, Ilza
AU  - Rizzolio, Flavio
AU  - Saponara, Simona
AU  - Spengler, Gabriella
AU  - Tsakovska, Ivanka
PY  - 2020
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3758
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3767
AB  - Overcoming multidrug resistance represents a major challenge for cancer treatment. In the search for new chemotherapeutics to treat malignant diseases, drug repurposing gained a tremendous interest during the past years. Repositioning candidates have often emerged through several stages of clinical drug development, and may even be marketed, thus attracting the attention and interest of pharmaceutical companies as well as regulatory agencies. Typically, drug repositioning has been serendipitous, using undesired side effects of small molecule drugs to exploit new disease indications. As bioinformatics gain increasing popularity as an integral component of drug discovery, more rational approaches are needed. Herein, we show some practical examples of in silico approaches such as pharmacophore modelling, as well as pharmacophore- and docking-based virtual screening for a fast and cost-effective repurposing of small molecule drugs against multidrug resistant cancers. We provide a timely and comprehensive overview of compounds with considerable potential to be repositioned for cancer therapeutics. These drugs are from diverse chemotherapeutic classes. We emphasize the scope and limitations of anthelmintics, antibiotics, antifungals, antivirals, antimalarials, antihypertensives, psychopharmaceuticals and antidiabetics that have shown extensive immunomodulatory, antiproliferative, pro-apoptotic, and antimetastatic potential. These drugs, either used alone or in combination with existing anticancer chemotherapeutics, represent strong candidates to prevent or overcome drug resistance. We particularly focus on outcomes and future perspectives of drug repositioning for the treatment of multidrug resistant tumors and discuss current possibilities and limitations of preclinical and clinical investigations.
PB  - Churchill Livingstone
T2  - Drug Resistance Updates
T1  - Repurposing old drugs to fight multidrug resistant cancers
VL  - 52
DO  - 10.1016/j.drup.2020.100713
SP  - 100713
ER  - 

@article{
author = "Dinić, Jelena and Efferth, Thomas and García-Sosa, Alfonso T. and Grahovac, Jelena and Padrón, José M. and Pajeva, Ilza and Rizzolio, Flavio and Saponara, Simona and Spengler, Gabriella and Tsakovska, Ivanka",
year = "2020",
abstract = "Overcoming multidrug resistance represents a major challenge for cancer treatment. In the search for new chemotherapeutics to treat malignant diseases, drug repurposing gained a tremendous interest during the past years. Repositioning candidates have often emerged through several stages of clinical drug development, and may even be marketed, thus attracting the attention and interest of pharmaceutical companies as well as regulatory agencies. Typically, drug repositioning has been serendipitous, using undesired side effects of small molecule drugs to exploit new disease indications. As bioinformatics gain increasing popularity as an integral component of drug discovery, more rational approaches are needed. Herein, we show some practical examples of in silico approaches such as pharmacophore modelling, as well as pharmacophore- and docking-based virtual screening for a fast and cost-effective repurposing of small molecule drugs against multidrug resistant cancers. We provide a timely and comprehensive overview of compounds with considerable potential to be repositioned for cancer therapeutics. These drugs are from diverse chemotherapeutic classes. We emphasize the scope and limitations of anthelmintics, antibiotics, antifungals, antivirals, antimalarials, antihypertensives, psychopharmaceuticals and antidiabetics that have shown extensive immunomodulatory, antiproliferative, pro-apoptotic, and antimetastatic potential. These drugs, either used alone or in combination with existing anticancer chemotherapeutics, represent strong candidates to prevent or overcome drug resistance. We particularly focus on outcomes and future perspectives of drug repositioning for the treatment of multidrug resistant tumors and discuss current possibilities and limitations of preclinical and clinical investigations.",
publisher = "Churchill Livingstone",
journal = "Drug Resistance Updates",
title = "Repurposing old drugs to fight multidrug resistant cancers",
volume = "52",
doi = "10.1016/j.drup.2020.100713",
pages = "100713"
}

Dinić, J., Efferth, T., García-Sosa, A. T., Grahovac, J., Padrón, J. M., Pajeva, I., Rizzolio, F., Saponara, S., Spengler, G.,& Tsakovska, I.. (2020). Repurposing old drugs to fight multidrug resistant cancers. in Drug Resistance Updates
Churchill Livingstone., 52, 100713.
https://doi.org/10.1016/j.drup.2020.100713

Dinić J, Efferth T, García-Sosa AT, Grahovac J, Padrón JM, Pajeva I, Rizzolio F, Saponara S, Spengler G, Tsakovska I. Repurposing old drugs to fight multidrug resistant cancers. in Drug Resistance Updates. 2020;52:100713.
doi:10.1016/j.drup.2020.100713 .

Dinić, Jelena, Efferth, Thomas, García-Sosa, Alfonso T., Grahovac, Jelena, Padrón, José M., Pajeva, Ilza, Rizzolio, Flavio, Saponara, Simona, Spengler, Gabriella, Tsakovska, Ivanka, "Repurposing old drugs to fight multidrug resistant cancers" in Drug Resistance Updates, 52 (2020):100713,
https://doi.org/10.1016/j.drup.2020.100713 . .

TY  - JOUR
AU  - Dinić, Jelena
AU  - Efferth, Thomas
AU  - García-Sosa, Alfonso T.
AU  - Grahovac, Jelena
AU  - Padrón, José M.
AU  - Pajeva, Ilza
AU  - Rizzolio, Flavio
AU  - Saponara, Simona
AU  - Spengler, Gabriella
AU  - Tsakovska, Ivanka
PY  - 2020
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3758
AB  - Overcoming multidrug resistance represents a major challenge for cancer treatment. In the search for new chemotherapeutics to treat malignant diseases, drug repurposing gained a tremendous interest during the past years. Repositioning candidates have often emerged through several stages of clinical drug development, and may even be marketed, thus attracting the attention and interest of pharmaceutical companies as well as regulatory agencies. Typically, drug repositioning has been serendipitous, using undesired side effects of small molecule drugs to exploit new disease indications. As bioinformatics gain increasing popularity as an integral component of drug discovery, more rational approaches are needed. Herein, we show some practical examples of in silico approaches such as pharmacophore modelling, as well as pharmacophore- and docking-based virtual screening for a fast and cost-effective repurposing of small molecule drugs against multidrug resistant cancers. We provide a timely and comprehensive overview of compounds with considerable potential to be repositioned for cancer therapeutics. These drugs are from diverse chemotherapeutic classes. We emphasize the scope and limitations of anthelmintics, antibiotics, antifungals, antivirals, antimalarials, antihypertensives, psychopharmaceuticals and antidiabetics that have shown extensive immunomodulatory, antiproliferative, pro-apoptotic, and antimetastatic potential. These drugs, either used alone or in combination with existing anticancer chemotherapeutics, represent strong candidates to prevent or overcome drug resistance. We particularly focus on outcomes and future perspectives of drug repositioning for the treatment of multidrug resistant tumors and discuss current possibilities and limitations of preclinical and clinical investigations.
PB  - Churchill Livingstone
T2  - Drug Resistance Updates
T1  - Repurposing old drugs to fight multidrug resistant cancers
VL  - 52
DO  - 10.1016/j.drup.2020.100713
SP  - 100713
ER  - 

@article{
author = "Dinić, Jelena and Efferth, Thomas and García-Sosa, Alfonso T. and Grahovac, Jelena and Padrón, José M. and Pajeva, Ilza and Rizzolio, Flavio and Saponara, Simona and Spengler, Gabriella and Tsakovska, Ivanka",
year = "2020",
abstract = "Overcoming multidrug resistance represents a major challenge for cancer treatment. In the search for new chemotherapeutics to treat malignant diseases, drug repurposing gained a tremendous interest during the past years. Repositioning candidates have often emerged through several stages of clinical drug development, and may even be marketed, thus attracting the attention and interest of pharmaceutical companies as well as regulatory agencies. Typically, drug repositioning has been serendipitous, using undesired side effects of small molecule drugs to exploit new disease indications. As bioinformatics gain increasing popularity as an integral component of drug discovery, more rational approaches are needed. Herein, we show some practical examples of in silico approaches such as pharmacophore modelling, as well as pharmacophore- and docking-based virtual screening for a fast and cost-effective repurposing of small molecule drugs against multidrug resistant cancers. We provide a timely and comprehensive overview of compounds with considerable potential to be repositioned for cancer therapeutics. These drugs are from diverse chemotherapeutic classes. We emphasize the scope and limitations of anthelmintics, antibiotics, antifungals, antivirals, antimalarials, antihypertensives, psychopharmaceuticals and antidiabetics that have shown extensive immunomodulatory, antiproliferative, pro-apoptotic, and antimetastatic potential. These drugs, either used alone or in combination with existing anticancer chemotherapeutics, represent strong candidates to prevent or overcome drug resistance. We particularly focus on outcomes and future perspectives of drug repositioning for the treatment of multidrug resistant tumors and discuss current possibilities and limitations of preclinical and clinical investigations.",
publisher = "Churchill Livingstone",
journal = "Drug Resistance Updates",
title = "Repurposing old drugs to fight multidrug resistant cancers",
volume = "52",
doi = "10.1016/j.drup.2020.100713",
pages = "100713"
}

Dinić, J., Efferth, T., García-Sosa, A. T., Grahovac, J., Padrón, J. M., Pajeva, I., Rizzolio, F., Saponara, S., Spengler, G.,& Tsakovska, I.. (2020). Repurposing old drugs to fight multidrug resistant cancers. in Drug Resistance Updates
Churchill Livingstone., 52, 100713.
https://doi.org/10.1016/j.drup.2020.100713

Dinić J, Efferth T, García-Sosa AT, Grahovac J, Padrón JM, Pajeva I, Rizzolio F, Saponara S, Spengler G, Tsakovska I. Repurposing old drugs to fight multidrug resistant cancers. in Drug Resistance Updates. 2020;52:100713.
doi:10.1016/j.drup.2020.100713 .

Dinić, Jelena, Efferth, Thomas, García-Sosa, Alfonso T., Grahovac, Jelena, Padrón, José M., Pajeva, Ilza, Rizzolio, Flavio, Saponara, Simona, Spengler, Gabriella, Tsakovska, Ivanka, "Repurposing old drugs to fight multidrug resistant cancers" in Drug Resistance Updates, 52 (2020):100713,
https://doi.org/10.1016/j.drup.2020.100713 . .